Tighter budgets and company acquisitions have altered investment in the cell and gene therapy (CGT) sector, new analysis finds.  According to a report from data and analytics company GlobalData, the CGT sector is transitioning as companies navigate a more selective and strategy-driven funding landscape.  While venture capital (VC) investment in CGTs has declined in recent years […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!